Induction of Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia Cells
Lymphokine-activated killer (LAK) cells are known to lyse fresh solid tumor cells in vitro , and clinical studies suggest that adoptive immunotherapy with LAK cells and interleukin-2 (IL-2) may be a promising approach in the treatment of solid tumors [2, 3]. As only few data are available on the LAK cell system in connection with human leukemia [4, 5], we investigated the induction of LAK cells against human leukemia cells in vitro and studied the augmentation of cytotoxic mechanisms which may be achieved by the combined application of different lymphokines or the coculturing of effector cells with tumor cells.
KeywordsHuman Leukemia Cell Adoptive Immunotherapy Acute Myeloblastic Leukemia Specific Lysis Daudi Cell
Unable to display preview. Download preview PDF.
- 2.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and in- terleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897PubMedCrossRefGoogle Scholar